Investview Stock Price, News & Analysis

Investview (OTCQB: INVU) reported Q3 2025 results and operational updates on Nov 13, 2025. Key Q3 metrics: Gross revenue $9.5M (down 24.3% YoY), Net revenue $9.1M (down 22.9% YoY), and net loss $0.9M (up 5.4% YoY). For the nine months, gross revenue $30.6M (down 28.7% YoY) and net loss $1.1M versus prior-year net income $1.4M.

Balance sheet highlights: $15.1M cash, $3.8M held in Bitcoin, total assets $27.5M, total liabilities $10.8M, and current ratio 2.44. The company repurchased >10.2M shares at an average $0.0179 per share under a $1M buyback program.

Segment notes: iGenius net revenue $7.1M; SAFETek mined 7.87 BTC in Q3; Renu Labs net revenue $1.1M; Opencash app on track for initial rollout in Q4 2025 into 2026.

Investview (OTCQB: INVU) reported Q2 2025 financial results showing mixed performance across its diversified business segments. The company reported Q2 net revenue of $10.0 million, down 23.5% year-over-year, and net income of $0.4 million, a 19.6% decrease from Q2 2024.

Key division performance: iGenius (financial education) generated $7.8M in revenue; SAFETek (crypto mining) mined 8.21 Bitcoin amid challenges; Renu Labs (wellness products) showed strong growth with $1.4M revenue, up 259.4% QoQ. The company maintains $16.2M in cash and is executing a $1M share buyback program.

Strategic initiatives include the upcoming Q4 2025 launches of myLife Wellness products and the Opencash trading platform, positioning INVU for future growth across fintech, wellness, and education sectors.

Investview (OTCQB: INVU) reported Q1 2025 financial results showing significant declines across key metrics. Gross revenue decreased 35.3% to $10.7M, while net revenue fell 36% to $10.0M compared to Q1 2024. The company reported a net operating loss of $0.4M, down from $1.9M profit in the prior year. Cash position decreased 22.1% to $17.5M from December 2024. Performance across divisions varied: - iGenius (financial education): Revenue down 32.5% to $8.8M - SAFETek (crypto mining): Revenue down 67.3% to $0.9M, produced 9.12 Bitcoin - Renu Labs (wellness products): Generated $0.4M in revenue - Opencash Securities (fintech): In development phase Despite challenges, the company maintains a strong balance sheet with a 2.29 current ratio and $14.2M working capital. The company continues strategic initiatives across its diversified portfolio spanning financial education, crypto mining, wellness products, and fintech services.

Investview (OTCQB: INVU) reported its full-year 2024 financial results, showing mixed performance across its business segments. The company recorded $55.4M in gross revenue, a 24% decrease from 2023, and $52.4M in net revenue, down 22.9%. Despite revenue declines, net cash from operations increased 36.9% to $8.3M.

Key financial metrics include: cash and equivalents up 7.4% to $22.5M, working capital increased 30.8% to $16.2M, and outstanding debt reduced by 10% to $3.2M. The company completed a significant share reduction, decreasing outstanding shares by 20.3% through strategic repurchases.

Notable developments include the acquisition of Renu Laboratories through myLife Wellness subsidiary, entering the health and wellness market, and the acquisition of Opencash Securities for future retail trading platform development. The company also announced a new $1M share repurchase program in March 2025.

Investview (OTCQB: INVU) has announced a significant stock repurchase program authorized by its board of directors. The company will repurchase up to $1 million worth of common stock through March 6, 2026. As of December 31, 2024, Investview had 1,859,231,786 common shares outstanding.

The repurchases will be executed through public open market purchases at market prices or through private transactions. The program will be funded from existing cash reserves and can be suspended or terminated at any time. The timing and volume of purchases will be influenced by market conditions, price, regulatory requirements, and other economic factors.

Investview operates multiple business units including financial education, manufacturing of wellness products, an early-stage trading platform, and a blockchain business focused on bitcoin mining. CEO Victor Oviedo stated that following their SEC settlement, the current share price doesn't reflect the company's intrinsic value and growth prospects.

Investview, Inc. (OTCQB: INVU) announced a settlement with the U.S. Securities and Exchange Commission (SEC) regarding an inquiry into its Apex Program, which involved the sale/leaseback of high-performance server equipment for bitcoin mining from July 2019 to June 2020. The SEC found that these were unregistered investment contracts, violating Sections 5(a) and 5(c) of the Securities Act of 1933. The company agreed to a $375,000 penalty and to cease further violations. Investview neither admitted nor denied the SEC's findings.

President James R. Bell highlighted proactive steps taken by current management, including winding down the Apex Program and returning invested capital with a premium to customers by December 2024. CEO Victor Oviedo emphasized the importance of resolving the matter to focus on growth initiatives and noted the company's full cooperation with the SEC and commitment to ethical standards.

Investview (OTCQB: INVU) reported Q3 2024 financial results showing decreased revenue but improved cash position. Gross revenue declined 39.1% to $12.6M, while net revenue decreased 38.7% to $11.7M compared to Q3 2023. The company reported a net loss of $0.7M, including a $977K non-cash impairment charge on mining equipment. Despite revenue challenges, cash position strengthened to $24.5M, up 16.9% from December 2023. The company announced plans to launch Opencash brokerage business in H1 2025 and expand into health and wellness through myLife Wellness Company and Renu Laboratories acquisition.

Investview (OTCQB: INVU) has acquired Renu Laboratories, a manufacturer of health, beauty and wellness products. The acquisition will launch a new health and wellness business unit called myLife Wellness, operating through a B2C direct-to-consumer model. Renu Labs brings proprietary products including advanced peptide serums and operates as an FDA-registered, cGMP-compliant facility. The merger is expected to be revenue accretive by Q4 2024-Q1 2025, leveraging Investview's existing network of over 15,000 global customers and members. The company aims to expand product offerings and enhance customer retention through its iGenius global network.

Investview, Inc. (OTCQB: INVU) reported its Q2 2024 financial results, showing mixed performance. Gross revenue decreased 26.0% to $13.8 million, while net revenue fell 24.1% to $13.1 million compared to Q2 2023. However, for the six months ended June 30, 2024, net income from operations increased 45.2% to $2.3 million. The company's cash position improved, with cash and cash equivalents up 13.1% to $23.7 million from December 31, 2023.

iGenius and SAFETek, Investview's operating subsidiaries, faced challenges due to global economic headwinds and industry-specific factors like Bitcoin halving. Despite these obstacles, the company remains focused on its strategic transformation plan, exploring new business channels and potential acquisitions to drive long-term growth.